Reviewing PTC Therapeutics Inc. (PTCT)’s and BioSpecifics Technologies Corp. (NASDAQ:BSTC)’s results

Both PTC Therapeutics Inc. (NASDAQ:PTCT) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) are each other’s competitor in the Biotechnology industry. Thus the contrast of their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PTC Therapeutics Inc. 264.73M 7.41 128.08M -1.70 0.00
BioSpecifics Technologies Corp. 29.81M 16.52 16.51M 2.40 29.63

Table 1 highlights PTC Therapeutics Inc. and BioSpecifics Technologies Corp.’s top-line revenue, earnings per share and valuation.


Table 2 represents PTC Therapeutics Inc. (NASDAQ:PTCT) and BioSpecifics Technologies Corp. (NASDAQ:BSTC)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
PTC Therapeutics Inc. -48.38% -32.7% -13.6%
BioSpecifics Technologies Corp. 55.38% 21.8% 20.7%

Risk and Volatility

PTC Therapeutics Inc.’s current beta is 2.07 and it happens to be 107.00% more volatile than S&P 500. In other hand, BioSpecifics Technologies Corp. has beta of 1.29 which is 29.00% more volatile than S&P 500.


2.7 and 2.6 are the respective Current Ratio and a Quick Ratio of PTC Therapeutics Inc. Its rival BioSpecifics Technologies Corp.’s Current and Quick Ratios are 48.4 and 48.4 respectively. BioSpecifics Technologies Corp. has a better chance of clearing its pay short and long-term debts than PTC Therapeutics Inc.

Analyst Recommendations

The Ratings and Recommendations for PTC Therapeutics Inc. and BioSpecifics Technologies Corp. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PTC Therapeutics Inc. 0 1 2 2.67
BioSpecifics Technologies Corp. 0 0 0 0.00

The upside potential is 39.96% for PTC Therapeutics Inc. with average target price of $47.

Institutional and Insider Ownership

PTC Therapeutics Inc. and BioSpecifics Technologies Corp. has shares held by institutional investors as follows: 87% and 61.3%. Insiders held 0.2% of PTC Therapeutics Inc. shares. Competitively, BioSpecifics Technologies Corp. has 2.5% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PTC Therapeutics Inc. 2.61% 11.31% -0.2% -16.26% 39.83% 0.96%
BioSpecifics Technologies Corp. 2.61% 9.45% 20.32% 40.89% 78.69% 17.36%

For the past year PTC Therapeutics Inc. was less bullish than BioSpecifics Technologies Corp.


On 10 of the 12 factors BioSpecifics Technologies Corp. beats PTC Therapeutics Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companyÂ’s lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companyÂ’s product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.